SMT201400159B - Formulazioni liquide si sali di 1-[2-(2,4-dimetilfenilsolfanil)fenil] piperazina - Google Patents
Formulazioni liquide si sali di 1-[2-(2,4-dimetilfenilsolfanil)fenil] piperazinaInfo
- Publication number
- SMT201400159B SMT201400159B SM201400159T SM201400159T SMT201400159B SM T201400159 B SMT201400159 B SM T201400159B SM 201400159 T SM201400159 T SM 201400159T SM 201400159 T SM201400159 T SM 201400159T SM T201400159 B SMT201400159 B SM T201400159B
- Authority
- SM
- San Marino
- Prior art keywords
- dimethylphenylsulfanil
- piperazine
- phenyl
- salts
- liquid formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Lubricants (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21454009P | 2009-04-24 | 2009-04-24 | |
DKPA200900531 | 2009-04-24 | ||
PCT/DK2010/050084 WO2010121621A1 (en) | 2009-04-24 | 2010-04-16 | Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
Publications (1)
Publication Number | Publication Date |
---|---|
SMT201400159B true SMT201400159B (it) | 2015-01-15 |
Family
ID=42669509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SM201400159T SMT201400159B (it) | 2009-04-24 | 2014-10-29 | Formulazioni liquide si sali di 1-[2-(2,4-dimetilfenilsolfanil)fenil] piperazina |
Country Status (35)
Country | Link |
---|---|
US (4) | US8940746B2 (pt) |
EP (1) | EP2421534B1 (pt) |
JP (1) | JP5722879B2 (pt) |
KR (1) | KR101779214B1 (pt) |
CN (2) | CN104693145A (pt) |
AR (2) | AR076400A1 (pt) |
AU (1) | AU2010238946B2 (pt) |
BR (1) | BRPI1015338C1 (pt) |
CA (1) | CA2759456C (pt) |
CL (1) | CL2011002631A1 (pt) |
CO (1) | CO6450649A2 (pt) |
CR (1) | CR20110554A (pt) |
DK (1) | DK2421534T3 (pt) |
DO (2) | DOP2011000319A (pt) |
EA (1) | EA021122B1 (pt) |
ES (1) | ES2512719T3 (pt) |
GE (1) | GEP20135938B (pt) |
HK (1) | HK1206732A1 (pt) |
HR (1) | HRP20140880T1 (pt) |
IL (1) | IL215362A0 (pt) |
MA (1) | MA33298B1 (pt) |
MX (1) | MX2011011119A (pt) |
MY (1) | MY155288A (pt) |
NZ (1) | NZ596431A (pt) |
PL (1) | PL2421534T3 (pt) |
PT (1) | PT2421534E (pt) |
RS (1) | RS53539B1 (pt) |
SG (1) | SG175124A1 (pt) |
SI (1) | SI2421534T1 (pt) |
SM (1) | SMT201400159B (pt) |
TN (1) | TN2011000504A1 (pt) |
TW (1) | TWI461224B (pt) |
UA (1) | UA106985C2 (pt) |
WO (1) | WO2010121621A1 (pt) |
ZA (1) | ZA201107731B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010121621A1 (en) | 2009-04-24 | 2010-10-28 | H. Lundbeck A/S | Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
WO2014044721A1 (en) | 2012-09-19 | 2014-03-27 | Sandoz Ag | Novel crystalline form of vortioxetine hydrobromide |
WO2015000833A1 (en) * | 2013-07-01 | 2015-01-08 | Lek Pharmaceuticals D.D. | 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form |
CN106103418A (zh) | 2014-01-31 | 2016-11-09 | 埃吉斯药物私人有限公司 | 沃替西汀盐的制备方法 |
CN104146953A (zh) * | 2014-07-24 | 2014-11-19 | 李雪梅 | 一种氢溴酸沃替西汀注射液 |
CN104119298B (zh) * | 2014-08-13 | 2016-08-24 | 北京蓝贝望生物医药科技股份有限公司 | 氢溴酸沃赛汀或氢溴酸沃替西汀 |
CN104119299B (zh) * | 2014-08-13 | 2016-08-17 | 北京蓝贝望生物医药科技股份有限公司 | 沃赛汀或沃替西汀的氢溴酸盐 |
GB201419261D0 (en) | 2014-10-29 | 2014-12-10 | Therakind Ltd | Formulations |
WO2016125190A2 (en) | 2015-02-04 | 2016-08-11 | Mylan Laboratories Limited | Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof |
JO3456B1 (ar) * | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
BR112017021277A2 (pt) | 2016-02-08 | 2018-06-26 | H Lundbeck As | Síntese de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina |
SG11201810644TA (en) | 2016-07-01 | 2018-12-28 | H Lundbeck As | Vortioxetine dosing regimes for fast onset of antidepressant effect |
CN106518807A (zh) * | 2016-09-17 | 2017-03-22 | 北京万全德众医药生物技术有限公司 | 乳酸沃替西汀晶型的制备方法 |
US10519121B2 (en) | 2016-12-30 | 2019-12-31 | Apicore Us Llc | Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts |
CN107011289A (zh) * | 2017-03-10 | 2017-08-04 | 万全万特制药(厦门)有限公司 | 沃替西汀β晶型的制备方法 |
GB2564887A (en) * | 2017-07-26 | 2019-01-30 | Azad Pharmaceutical Ingredients Ag | New route of synthesis to vortioxetine salts |
WO2021198778A1 (en) | 2020-04-03 | 2021-10-07 | H. Lundbeck A/S | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
CA2521258C (en) | 2003-04-04 | 2009-12-01 | H. Lundbeck A/S | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors |
PL2044020T3 (pl) * | 2006-06-16 | 2011-09-30 | H Lundbeck As | Krystaliczne postaci 4-[2-(4-metylofenylosulfanylo)-fenylo]piperydyny z równoczesnym hamowaniem wychwytu zwrotnego serotoniny i norepinefryny do leczenia bólu neuropatycznego |
FI2044043T5 (fi) * | 2006-06-16 | 2023-11-21 | H Lundbeck A/S | 1-[2-(2,4-dimetyylifenyylisulfanyyli)fenyyli]piperatsiini yhdisteenä, jolla on yhdistetty serotonin takaisinotto-, 5-HT3- ja 5-HT1A -aktiivisuus käytettäväksi kognitiivisten häiriöiden hoitoon |
TWI405588B (zh) * | 2007-03-20 | 2013-08-21 | Lundbeck & Co As H | 4-〔2-(4-甲苯基硫基)-苯基〕哌啶之鹽類的液體調配物 |
TW200848411A (en) * | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
WO2010121621A1 (en) | 2009-04-24 | 2010-10-28 | H. Lundbeck A/S | Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
-
2010
- 2010-04-16 WO PCT/DK2010/050084 patent/WO2010121621A1/en active Application Filing
- 2010-04-16 PL PL10714164T patent/PL2421534T3/pl unknown
- 2010-04-16 EP EP10714164.0A patent/EP2421534B1/en active Active
- 2010-04-16 KR KR1020117025009A patent/KR101779214B1/ko active IP Right Grant
- 2010-04-16 PT PT107141640T patent/PT2421534E/pt unknown
- 2010-04-16 ES ES10714164.0T patent/ES2512719T3/es active Active
- 2010-04-16 UA UAA201113335A patent/UA106985C2/uk unknown
- 2010-04-16 NZ NZ596431A patent/NZ596431A/xx unknown
- 2010-04-16 US US13/265,564 patent/US8940746B2/en active Active
- 2010-04-16 MX MX2011011119A patent/MX2011011119A/es active IP Right Grant
- 2010-04-16 RS RSP20140505 patent/RS53539B1/en unknown
- 2010-04-16 CN CN201510093852.4A patent/CN104693145A/zh active Pending
- 2010-04-16 EA EA201171287A patent/EA021122B1/ru not_active IP Right Cessation
- 2010-04-16 GE GEAP201012423A patent/GEP20135938B/en unknown
- 2010-04-16 TW TW099111946A patent/TWI461224B/zh active
- 2010-04-16 AU AU2010238946A patent/AU2010238946B2/en active Active
- 2010-04-16 SI SI201030759T patent/SI2421534T1/sl unknown
- 2010-04-16 DK DK10714164.0T patent/DK2421534T3/da active
- 2010-04-16 MA MA34385A patent/MA33298B1/fr unknown
- 2010-04-16 CN CN2010800171058A patent/CN102405048A/zh active Pending
- 2010-04-16 BR BRPI1015338A patent/BRPI1015338C1/pt active IP Right Grant
- 2010-04-16 CA CA2759456A patent/CA2759456C/en active Active
- 2010-04-16 SG SG2011073384A patent/SG175124A1/en unknown
- 2010-04-16 MY MYPI2011004813A patent/MY155288A/en unknown
- 2010-04-16 JP JP2012506342A patent/JP5722879B2/ja active Active
- 2010-04-23 AR ARP100101364A patent/AR076400A1/es not_active Application Discontinuation
-
2011
- 2011-09-25 IL IL215362A patent/IL215362A0/en active IP Right Grant
- 2011-10-07 TN TNP2011000504A patent/TN2011000504A1/en unknown
- 2011-10-19 CR CR20110554A patent/CR20110554A/es unknown
- 2011-10-20 DO DO2011000319A patent/DOP2011000319A/es unknown
- 2011-10-21 ZA ZA2011/07731A patent/ZA201107731B/en unknown
- 2011-10-21 CL CL2011002631A patent/CL2011002631A1/es unknown
- 2011-10-24 CO CO11143307A patent/CO6450649A2/es active IP Right Grant
-
2012
- 2012-07-27 DO DO2012000211A patent/DOP2012000211A/es unknown
-
2014
- 2014-09-15 HR HRP20140880AT patent/HRP20140880T1/hr unknown
- 2014-10-29 SM SM201400159T patent/SMT201400159B/xx unknown
- 2014-12-11 US US14/567,003 patent/US9475748B2/en active Active
-
2015
- 2015-07-29 HK HK15107256.7A patent/HK1206732A1/xx unknown
-
2016
- 2016-09-21 US US15/271,543 patent/US10034876B2/en active Active
-
2018
- 2018-06-27 US US16/020,799 patent/US10857149B2/en active Active
-
2021
- 2021-05-10 AR ARP210101276A patent/AR122051A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SMT201400159B (it) | Formulazioni liquide si sali di 1-[2-(2,4-dimetilfenilsolfanil)fenil] piperazina | |
HK1165955A1 (en) | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine 1-[2-(24-)] | |
ME02307B (me) | Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol- 3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr | |
IL220155B (en) | History of 2, 4-(phenyl-amine-)di-converted pyrimidines for use as kinase inhibitors | |
SMT201300063B (it) | Procedimento per preparazione di composti piperazinici e loro sali idrocloruri | |
DK3686194T3 (da) | 2-(2,4,5-substitueret-anilino)pyrimidinforbindelser | |
IL217914A0 (en) | New compositions of 1-[2-(2'4-dimethyl-phenylsulfanyl)-phenyl]piperazine | |
BRPI0921596A2 (pt) | Compostos de 4-[2-(2-fluorofenoximetil) fenil] piperidina | |
ITMI20110647A1 (it) | Procedimento migliorato per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib. | |
HK1140949A1 (en) | Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl) phenyl]piperidine 4-[2-(4-)-] | |
AP3583A (en) | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine | |
CY1115793T1 (el) | Υγρα σκευασματα αλατων 1-[2-(2,4-διμεθυλοφαινυλοσουλφανυλο)φαινυλο]πιπεραζινης | |
UA19948S (uk) | Комплект етикеток для горілки «цельсій» | |
ITBG20070014U1 (it) | Dispositivo di taglio fissa - erogatore per bottiglie di superalcolici | |
IT1395936B1 (it) | Sali di febuxostat | |
ITTO20060066U1 (it) | Abbeveratoio per avicoltura |